PremiumThe FlyJazz Pharmaceuticals price target lowered to $155 from $167 at Baird Jazz Pharmaceuticals price target raised to $216 from $213 at BofA Jazz Pharmaceuticals price target lowered to $166 from $183 at Morgan Stanley PremiumRatingsOptimistic Buy Rating for Jazz Pharmaceuticals Amid Growth Prospects and Strategic Positioning Closing Bell Movers: Sarepta falls 21% after earnings and guidance cut Jazz Pharmaceuticals cuts FY25 adjusted EPS view to $4.00-$5.60 PremiumThe FlyJazz Pharmaceuticals receives CHMP positive opinion for zanidatamab Jazz Pharmaceuticals Completes Acquisition of Chimerix Buy Rating Maintained for Jazz Pharmaceuticals Amid Overreaction to Tariff Concerns and Strategic Mitigation Plans 
